X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Advance price notification: A transparency measure that fails patients

By Saumil Pandya and Emily Donaldson  |    March 29, 2018
Most transparency reforms aim to correct perceived misaligned incentives in the biopharmaceutical marketplace. However, many efforts to mandate information flow in the private market have serious...   Read More

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

By Holly Campbell  |    March 27, 2018
Today, as part of the Let’s Talk About Cost campaign, PhRMA unveiled new advertisements highlighting how the use of copay accumulator programs by insurance companies and other middlemen could...   Read More

ICYMI – Two PBM reports show dramatic slowdown in medicine spending growth

By Holly Campbell  |    March 2, 2018
Newly released pharmacy benefit manager (PBM) data show medicine spending is growing at the slowest rate in years. After accounting for discounts and rebates negotiated with biopharmaceutical...   Read More

Copay coupons can help ease patients’ out-of-pocket costs

By Holly Campbell  |    February 16, 2018
Each year, middlemen, like pharmacy benefit managers (PBMs) and insurers, shift more of the costs of health care to patients. Ensuring patients have affordable access to their medicines is the top...   Read More

Why won’t the insurance industry tell the truth about medicine costs?

By Robert Zirkelbach  |    May 10, 2017
Discussions about the cost of medicines are important. We recognize that many patients are struggling to access the medicines they need, and we want to work with policymakers and other health care...   Read More

What They Aren’t Telling You About Medicine Prices

By Holly Campbell  |    May 6, 2015
Recent cries from Bloomberg and The New York Times of “skyrocketing” medicine prices make for great headlines.  But what’s not being talked about is that these claims are based solely on the list...   Read More

New Report: Forecasts for Specialty Medicines Have Been Overstated

By Jennifer Bryant  |    February 9, 2015
According to a new report from actuaries Gabriela Dieguez, Bruce Pyenson and Jennifer Carioto, at Milliman, major pharmacy benefits managers (PBMs) often overestimate future spending on specialty...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."